Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2009

View Archived Issues

Recent Roche patent describes new NNRTIs for HIV infection

GlaxoSmithKline divulges new calcium receptor antagonists for osteoporosis

New CaSR antagonists discovered by Pfizer researchers

Novel microtubule-stabilizing agents discovered by the University of Pennsylvania and Kosan

Novel tachykinin NK1 receptor antagonists identified by Merck & Co. researchers

Recent Takeda patent reports new renin inhibitors with antihypertensive properties

Synta completes enrollment in phase III SYMMETRYSM trial

Auxilium completes enrollment in phase IIb Xiaflex trial

Phase II IMPACT-DCM clinical trial of Aastrom's CRCs placed on clinical hold after SAE

New DPP-4 inhibitors discovered by Santhera and Biovitrum researchers

Rexahn initiates phase IIa clinical trial of Serdaxin in major depressive disorder

Cephalon exercises option to license worldwide rights to ImmuPharma's Lupuzor for SLE

Researchers report development of tetracyclic indole inhibitors of HCV NS5B-polymerase

Medarex receives milestone payment from MedImmune for allowance of IND for MEDI-546

Drug delivery innovation: Selective release of DNA oligonucleotides from gold nanorods with lasers

Acorda submits NDA for Fampridine-SR for walking improvement in MS

Cenix collaborates with Boehringer Ingelheim for RNAi-based target discovery

Idera achieves clinical milestone under cancer collaboration with Merck KGaA

Anavex scales up Anavex 2-73 for phase I Alzheimer's disease study

Ligand announces phase IIb results for PS4-33540 in hypertension

Phase III study shows Tarceva plus Avastin improves survival in lung cancer

Safinamide significantly improved motor function in Parkinson's disease

Medgenics presents positive data from phase I/II Epodure trial in anemia

ESBATech advances antibody fragment into phase Ib/IIa trials in ophthalmology

Transcept completes merger with Novacea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...